Insider Sell: John Fleming Sells 500 Shares of Usana Health Sciences Inc (USNA)

🗝️ Key Points

• On June 9, 2025, John Fleming, a Director at Usana Health Sciences Inc (USNA, Financial), sold 500 shares of the company, according to a SEC Filing.
• Following this transaction, the insider now owns 4,200 shares of the company.
• Usana Health Sciences Inc is a company that develops and manufactures high-quality nutritional supplements, personal care, and weight management products.

On June 9, 2025, John Fleming, a Director at Usana Health Sciences Inc (USNA, Financial), sold 500 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 4,200 shares of the company.
Usana Health Sciences Inc is a company that develops and manufactures high-quality nutritional supplements, personal care, and weight management products. The company operates in various markets worldwide, providing health and wellness solutions to its customers.
Over the past year, John Fleming has sold a total of 2,000 shares and has not purchased any shares. The insider transaction history for Usana Health Sciences Inc indicates that there have been no insider buys in the past year, while there have been 16 insider sells during the same period.
On the day of the recent sale, shares of Usana Health Sciences Inc were trading at $29.66 each, giving the stock a market cap of $571.819 million. The company’s price-earnings ratio stands at 16.87, which is lower than the industry median of 17.51 but higher than the company’s historical median price-earnings ratio.
With a trading price of $29.66 and a GF Value of $47.76, Usana Health Sciences Inc has a price-to-GF-Value ratio of 0.62. This suggests that the stock is considered a “Possible Value Trap, Think Twice” based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on three factors:
– Historical multiples (price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow) that the stock has traded at.
– A GuruFocus adjustment factor based on the company’s past returns and growth.
– Future estimates of business performance from Morningstar analysts.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

MORE IN INSIDE INVESTMENT NEWS

Citigroup beats second-quarter estimates as markets and banking revenues jump

Published: Tuesday, July 15, 2025 · 12:38 PM

JPMorgan Chase tops estimates on stronger-than-expected trading, investment banking

Published: Tuesday, July 15, 2025 · 11:25 AM